Skjeldestad F E, Hagen B, Lie A K, Isaksen C
Department of Obstetrics and Gynecology, Medical Faculty, Norwegian University of Science and Technology, Trondheim, Norway.
Obstet Gynecol. 1997 Sep;90(3):428-33. doi: 10.1016/s0029-7844(97)00276-7.
To assess the risk of residual and recurrent disease after carbon dioxide laser conization treatment for high-grade lesions of the cervix uteri, and thus to refine intervals for follow-up.
The study population comprised all women treated for cervical intraepithelial neoplasia grade II-III over a 10-year period (1983-1992). All women who resided within the county for the entire follow-up period were followed for residual or recurrent disease, verified histologically until the closure date of January 31, 1996. The cumulative incidence of recurrent disease was assessed by survival analyses, and logistic regression was used to predict clinical features at initial treatment that were associated with the risk of residual or recurrent disease.
Only 19 of 1081 women (1.8%) were lost to follow-up. Residual disease was diagnosed in 20 (1.9%) study participants. The cumulative incidence of recurrent disease was extremely low, increasing nearly linearly with an annual incidence of three per 1000 woman-years observed. Involved resection margins were associated significantly with both residual disease (crude odds ratio [OR] 18.1; 95% confidence interval [CI] 5.2, 64.0) and recurrent disease (adjusted OR 3.0; 95% CI 1.2, 7.5) when compared with disease-free resection margins as reference.
We recommend a differential follow-up interval depending upon the histologic evaluation of cone margins. If there is no residual disease, women who have free resection margins should return at a 3-year interval for follow-up. Women who have disease extended to the cone margins are recommended Papanicolaou smears at annual intervals through the fourth postoperative year before returning at a 3-year interval as practiced in the general screening program.
评估二氧化碳激光锥切术治疗子宫颈高级别病变后残留及复发病变的风险,从而优化随访间隔。
研究人群包括在10年期间(1983 - 1992年)接受治疗的所有子宫颈上皮内瘤变II - III级的女性。所有在整个随访期间居住在该县的女性均接受残留或复发病变的随访,通过组织学检查进行确认,直至1996年1月31日截止日期。复发病变的累积发病率通过生存分析进行评估,逻辑回归用于预测初始治疗时与残留或复发病变风险相关的临床特征。
1081名女性中仅有19名(1.8%)失访。20名(1.9%)研究参与者被诊断为残留病变。复发病变的累积发病率极低,以每1000女性年3例的年发病率几乎呈线性增加。与切缘无病变作为对照相比,切缘受累与残留病变(粗比值比[OR] 18.1;95%置信区间[CI] 5.2, 64.0)和复发病变(校正OR 3.0;95% CI 1.2, 7.5)均显著相关。
我们建议根据锥切切缘的组织学评估采用不同的随访间隔。如果没有残留病变,切缘无病变的女性应每3年复诊进行随访。对于切缘有病变的女性,建议在术后第4年每年进行巴氏涂片检查,之后按照一般筛查程序每3年复诊一次。